About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 63   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
ORIGINAL ARTICLE
Year : 2018  |  Volume : 25  |  Issue : 2  |  Page : 103-107

Outcome analysis of visual acuity and side effect after ruthenium-106 plaque brachytherapy for medium-sized choroidal melanoma


1 Department of Surgery, Collage of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE; Department of Ophthalmology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
2 Department of Radiation Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada
3 Department of Oncology, Henderson Research Unit, McMaster University, Hamilton, Ontario, Canada
4 Department of Ophthalmology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada

Correspondence Address:
Dr. Tahra AlMahmoud
College of Medicine and Health Sciences, United Arab Emirates University, P. O. Box: 17666, Al Ain, United Arab Emirates

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/meajo.MEAJO_198_16

Rights and Permissions

PURPOSE: The purpose of this study is to report on treatment outcomes for medium-sized choroidal melanoma treated with Ruthenium-106 (Ru-106) plaque brachytherapy. METHODS: A retrospective case series of 28 patients received Ru-106 brachytherapy treatment for choroidal melanoma. The prescribed tumor dose was 85 Gy to a depth of 5 mm. RESULTS: Median follow-up was 31.2 months. At 12 and 24-month postirradiation, the best corrected visual acuity ≥20/70 (LogMar ≥−0.54) was 53.8% and 64.2%, respectively. Median time to tumor regression was estimated to be 10 months (95% CI = 9–18 months), with 100% of response rate by 32 months. Radiation-induced side effects were limited, and there were no postradiation enucleations. CONCLUSIONS: The majority of patients maintained good visual acuity, with no enucleations and minimal side effects. In this cohort, the Ru-106 plaque brachytherapy proved to be an efficacious and safe treatment option for patients with medium-sized choroidal melanomas with a maximal tumor height of 5 mm.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed727    
    Printed28    
    Emailed0    
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal